Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Others

United Therapeutics (UTHR) Deferred Taxes (2026)

United Therapeutics' Deferred Taxes history spans 4 years, with the latest figure at $30.4 million for Q3 2012.

On a quarterly basis, Deferred Taxes rose 58.03% to $30.4 million in Q3 2012 year-over-year; TTM through Sep 2012 was $113.8 million, a 88.51% increase, with the full-year FY2025 number at $97.7 million, up 252.42% from a year prior.
Deferred Taxes hit $30.4 million in Q3 2012 for United Therapeutics, down from $31.0 million in the prior quarter.
Over the last five years, Deferred Taxes for UTHR hit a ceiling of $35.7 million in Q2 2011 and a floor of -$5.0 million in Q4 2010.
Historically, Deferred Taxes has averaged $16.4 million across 4 years, with a median of $18.6 million in 2010.
The widest YoY moves for Deferred Taxes: up 722.55% in 2010, down 188.6% in 2010.
Tracing UTHR's Deferred Taxes over 4 years: stood at -$1.7 million in 2009, then plummeted by 188.6% to -$5.0 million in 2010, then skyrocketed by 481.52% to $19.2 million in 2011, then skyrocketed by 58.03% to $30.4 million in 2012.
Business Quant data shows Deferred Taxes for UTHR at $30.4 million in Q3 2012, $31.0 million in Q2 2012, and $33.2 million in Q1 2012.